# Kimberly Nearing

> Kimberly Nearing is the Chief Business Officer of MaveriX Oncology, a Palo Alto biotech building tumor-selective small molecule drug conjugates. She is a Venture Partner at BVCF (Bioveda China Fund) and spent over a decade as Managing Director and Head of Life Sciences at the Hong Kong-based Cedrus Group, building bridges for capital and deals between the U.S., Europe, and Greater China. With early operating years at Amgen, Merck, and IBM Healthcare and a master's from Harvard, she pairs deep biotech operating experience with the relationships that move money across the Pacific.

- **Role:** Chief Business Officer at MaveriX Oncology
- **Organizations:** MaveriX Oncology, Inc., BVCF Management Ltd. (Bioveda China Fund), Expression Therapeutics, Cedrus Group, BayHelix, AsedaSciences, Amato and Partners
- **Nationality:** American
- **Education:** Master of Science, with Honors, Harvard University, B.A. in Economics, with Distinction/Honors, University of Michigan
- **Known for:** Chief Business Officer at MaveriX Oncology, leading business and corporate development for a tumor-selective small molecule drug conjugate platform, Venture Partner at BVCF (Bioveda China Fund), one of the established cross-border life sciences investment firms bridging the U.S. and Greater China, Over a decade as Managing Director and Head of Life Sciences at the Cedrus Group

## Career timeline

- **1994-2000** — Senior Product Manager / Marketing Director, Business Development, Special Projects Group at Amgen
- **2000-2003** — Business Development Executive at IBM Healthcare Group
- **2000s-2010s** — Managing Director, Head of Life Sciences at Cedrus Group, a Hong Kong-based global boutique investment firm (over a decade)
- **2019** — Joined BVCF Management Ltd. as Venture Partner on the Investment Team (November 2019)
- **2020** — Chief Business Officer at MaveriX Oncology, Expression Therapeutics, and Ethismos Research
- **Recent** — Managing Director at Amato and Partners; elected to BayHelix Board of Directors

## Achievements

- Chief Business Officer at MaveriX Oncology, leading business and corporate development for a tumor-selective small molecule drug conjugate platform
- Venture Partner at BVCF (Bioveda China Fund), one of the established cross-border life sciences investment firms bridging the U.S. and Greater China
- Over a decade as Managing Director and Head of Life Sciences at the Cedrus Group
- Elected to the Board of Directors of BayHelix, the influential network of Chinese life sciences leaders
- Independent Director at MaveriX Oncology and Board/Executive Committee member at a Washington D.C. foundation (RVF)

## Latest updates

- **2019-11** — Joined BVCF Management as Venture Partner on the investment team
- **2020** — Serving as Chief Business Officer across MaveriX Oncology, Expression Therapeutics, and Ethismos Research

## Links

- Website: https://maverixoncology.com
- LinkedIn: https://www.linkedin.com/in/kimnearing/

---

Profile page: https://yespress.io/kimberly-nearing
Published by YesPress — https://yespress.io
Last updated: 2026-06-11